Table 3.
Basic characteristics and prognosis stratified by changes in BRCAness status (n = 41).
| BRCAness +/− (n = 12) |
BRCAness +/+ (n = 7) |
BRCAness −/− (n = 22) |
P value 1* | P value 2* | |
|---|---|---|---|---|---|
| Tumor size | |||||
| T1 | 1 (8.3) | 1 (14.3) | 2 (9.1) | 0.914 | 0.974 |
| T2 | 7 (58.3) | 3 (42.9) | 14 (63.6) | ||
| T3 | 3 (25.0) | 2 (28.6) | 4 (18.2) | ||
| T4 | 1 (8.3) | 1 (14.3) | 2 (9.1) | ||
| Lymph node status | |||||
| N0 | 6 (50.0) | 3 (42.9) | 10 (45.5) | 0.405 | 0.748 |
| N1 | 6 (50.0) | 3 (42.9) | 11 (50.0) | ||
| N2 | 0 (0) | 1 (14.3) | 1 (4.5) | ||
| TNM stage | |||||
| I | 0 (0) | 1 (14.3) | 1 (4.5) | 0.324 | 0.724 |
| II | 8 (66.7) | 3 (42.9) | 15 (68.2) | ||
| III | 4 (33.3) | 3 (42.9) | 6 (27.3) | ||
| Nuclear grade | |||||
| I | 1 (10.0) | 0 (0) | 8 (44.4) | 0.638 | 0.166 |
| II | 3 (30.0) | 3 (42.9) | 4 (22.2) | ||
| III | 6 (60.0) | 4 (57.1) | 6 (33.3) | ||
| Molecular subtype | |||||
| Luminal | 2 (16.7) | 0 (0) | 16 (72.7) | 0.354 | 0.001a |
| HER2 | 1 (8.3) | 0 (0) | 3 (13.6) | ||
| TNBC | 9 (75.0) | 7 (100.0) | 3 (13.6) | ||
| Clinical response | |||||
| CR + PR | 9 (75.0) | 2 (28.6) | 18 (81.8) | 0.074 | 0.677 |
| PD + SD | 3 (25.0) | 5 (71.4) | 4 (18.2) | ||
| Prognosis | |||||
| 5 years-DFS | 40.0% | 28.6% | 100.0% | 0.611 | < 0.001a |
| 5 years-OS | 78.6% | 83.3% | 100.0% | 0.757 | 0.001a |
Data presented as mean and range or n (%).
*P Value 1: BRCAness +/− (n = 12) versus BRCAness +/+ (n = 7).
*P Value 2: BRCAness +/− (n = 12) versus BRCAness −/− (n = 22).
aStatistically significant difference.